Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

VaxGen Awarded $80.3M For Anthrax Vaccine Development

Oct. 2, 2003

By Aaron Lorenzo

VaxGen Awarded $80.3M For Anthrax Vaccine Development

Oct. 2, 2003

By Aaron Lorenzo

Pushing Its CNS Programs, Acorda Files For $75M IPO

Oct. 1, 2003

By Aaron Lorenzo

Inex Begins Rolling NDA For Onco TCS In Non-Hodgkin's

Oct. 1, 2003

By Aaron Lorenzo

Inex Begins Rolling NDA For Onco TCS In Non-Hodgkin's

Oct. 1, 2003

By Aaron Lorenzo

Pushing Its CNS Programs, Acorda Files For $75M IPO

Oct. 1, 2003

By Aaron Lorenzo

NIH Disperses Nearly $90M For HIV Vaccines, Other Diseases

Sep. 30, 2003

By Aaron Lorenzo

NIH Disperses Nearly $90M For HIV Vaccines, Other Diseases

Sep. 30, 2003

By Aaron Lorenzo

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Sep. 29, 2003

By Aaron Lorenzo

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Sep. 29, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...